Scher HI - Search Results

1

Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.

Rathkopf DE, Larson SM, Anand A, Morris MJ, Slovin SF, Shaffer DR, Heller G, Carver B, Rosen N, Scher HI. Rathkopf DE, et al. Among authors: scher hi. Cancer. 2015 Nov 1;121(21):3853-61. doi: 10.1002/cncr.29578. Epub 2015 Jul 15. Cancer. 2015. PMID: 26178426 Free PMC article. Clinical Trial.

2

Hormone refractory prostatic cancer: the role of radiolabelled diphosphonates and growth factor inhibitors.

Scher HI, Curley T, Yeh S, Tong W, O'Moore PV, Larson S. Scher HI, et al. Adv Exp Med Biol. 1992;324:115-29. doi: 10.1007/978-1-4615-3398-6_12. Adv Exp Med Biol. 1992. PMID: 1283494 Review. No abstract available.

3

Therapeutic alternatives for hormone-refractory prostatic cancer.

Scher HI, Curley T, Yeh S, Iversen JM, O'Dell M, Larson SM. Scher HI, et al. Semin Urol. 1992 Feb;10(1):55-64. Semin Urol. 1992. PMID: 1373515 Review.

4

Acute arterial thrombosis after escalated-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy with recombinant granulocyte colony-stimulating factor. A possible new recombinant granulocyte colony-stimulating factor toxicity.

Conti JA, Scher HI. Conti JA, et al. Among authors: scher hi. Cancer. 1992 Dec 1;70(11):2699-702. doi: 10.1002/1097-0142(19921201)70:11<2699::aid-cncr2820701122>3.0.co;2-c. Cancer. 1992. PMID: 1384952

5

Spinal epidural tumor in patients with prostate cancer. Clinical and radiographic predictors of response to radiation therapy.

Zelefsky MJ, Scher HI, Krol G, Portenoy RK, Leibel SA, Fuks ZY. Zelefsky MJ, et al. Among authors: scher hi. Cancer. 1992 Nov 1;70(9):2319-25. doi: 10.1002/1097-0142(19921101)70:9<2319::aid-cncr2820700918>3.0.co;2-8. Cancer. 1992. PMID: 1394060

6

Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression.

Motzer RJ, Nanus DM, O'Moore P, Scher HI, Bajorin DF, Reuter V, Tong WP, Iversen J, Louison C, Albino AP, et al. Motzer RJ, et al. Among authors: scher hi. Cancer Res. 1992 Oct 15;52(20):5775-9. Cancer Res. 1992. PMID: 1394202 Clinical Trial.

7

Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy.

Petrylak DP, Scher HI, Li Z, Myers CE, Geller NL. Petrylak DP, et al. Among authors: scher hi. Cancer. 1992 Dec 15;70(12):2870-8. doi: 10.1002/1097-0142(19921215)70:12<2870::aid-cncr2820701225>3.0.co;2-f. Cancer. 1992. PMID: 1451069

8

Carboplatin, etoposide, and bleomycin for patients with poor-risk germ cell tumors.

Motzer RJ, Cooper K, Geller NL, Pfister DG, Lin SY, Bajorin D, Scher HI, Herr H, Fair W, Morse M, et al. Motzer RJ, et al. Among authors: scher hi. Cancer. 1990 Jun 1;65(11):2465-70. doi: 10.1002/1097-0142(19900601)65:11<2465::aid-cncr2820651112>3.0.co;2-7. Cancer. 1990. PMID: 1692505

9

Use of adaptive control with feedback to individualize suramin dosing.

Scher HI, Jodrell DI, Iversen JM, Curley T, Tong W, Egorin MJ, Forrest A. Scher HI, et al. Cancer Res. 1992 Jan 1;52(1):64-70. Cancer Res. 1992. PMID: 1727387

10

Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors.

Seidman AD, Scher HI, Heinemann MH, Bajorin DF, Sternberg CN, Dershaw DD, Silverberg M, Bosl GJ. Seidman AD, et al. Among authors: scher hi. Cancer. 1991 Dec 15;68(12):2561-5. doi: 10.1002/1097-0142(19911215)68:12<2561::aid-cncr2820681205>3.0.co;2-g. Cancer. 1991. PMID: 1933802 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

696 results

Search Page

Filters